Gualou Xiebai Decoction, a Traditional Chinese Medicine, Prevents Cardiac Reperfusion Injury of Hyperlipidemia Rat via Energy Modulation

Frontiers in Physiology

Jing-Yu Fan¹  Yu-Ying Liu¹  Jing-Yan Han¹  Xiao-Hong Wei¹  Yang Yu²  Xin-Sheng Yao²  Wei-Yang Zhang³  Hua Zhou³  Lu-Lu Yan⁴  Li Yan⁴  Chun-Shui Pan⁴ 

[1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China;Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, China;State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China;Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China;

关键词: cardiac function;    myocardial structure;    ATP synthase subunit;    apoptosis;    Rho-associated protein kinase;    Rho GTPases;   

DOI  :  10.3389/fphys.2018.00296

来源: DOAJ

【 摘 要 】

Background: Gualou Xiebai Decoction (GLXB) is a classic prescription of Chinese medicine used for the treatment of cardiac problems. The present study was designed to explore the effect and mechanism of GLXB on ischemia/reperfusion (I/R) induced disorders in myocardial structure and function, focusing on the regulation of energy metabolism and the RhoA/ROCK pathway.Methods: After hyperlipidemic rat model was established by oral administration of high fat diet, the rats were treated with GLXB for 6 weeks and subjected to 30 min occlusion of the left anterior descending coronary artery (LADCA) followed by 90 min reperfusion to elicit I/R challenge. Myocardial infarct size was assessed by Evans blue-TTC staining. Myocardial blood flow (MBF) and cardiac function were evaluated. Enzyme-linked immunosorbent assay was performed to examine the content of ATP, ADP, AMP, CK, CK-MB, LDH, cTnT, cTnI, and IL-6. Double staining of F-actin and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling was conducted to assess myocardial apoptosis. Expressions of ATP synthase subunit δ (ATP 5D), and RhoA and ROCK were determined by Western blotting.Results: Administration with GLXB at high dose for 6 weeks protected heart against I/R-induced MBF decrease, myocardial infarction and apoptosis, ameliorated I/R-caused impairment of cardiac function and myocardial structure, restored the decrease in the ratio of ADP/ATP and AMP/ATP, and the expression of ATP 5D with inhibiting the expression of RhoA and ROCK.Conclusions: Treatment with GLXB effectively protects myocardial structure and function from I/R challenge, possibly via regulating energy metabolism involving inactivation of RhoA/ROCK signaling pathway.

【 授权许可】

Unknown